Noninvasive markers of fibrosis and inflammation in clinical practice: Prospective comparison with liver biopsy

Institute of Hepatology, UCL, Medical School, Chenies Mews.
European journal of gastroenterology & hepatology (Impact Factor: 2.25). 10/2009; 22(4):474-80. DOI: 10.1097/MEG.0b013e328332dd0a
Source: PubMed


The efficiency of transient elastography for the assessment of liver fibrosis has been evaluated mainly in patients with chronic hepatitis C and chronic hepatitis B, with few studies with nonviral chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and nonalcoholic steatohepatitis. In this study, we examined the value of transient elastography in a number of groups in comparison with the Fibrotest/Actitest (FT/AT), using the liver biopsy (LB) as the reference standard.
An unselected and consecutive group of 65 patients had an LB either as part of an initial diagnosis or of a follow-up assessment, and in addition had a transient elastography measurement [Fibroscan (FS)] and serum blood tests FT/AT performed before the LB. The group consisted of patients diagnosed with a variety of CLD: chronic hepatitis C (n=27), chronic hepatitis B (n=8), alcoholic liver disease (n=14), autoimmune hepatitis (n=13) and nonalcoholic steatohepatitis (n=4).
FS optimal cutoff values were 9.70 kPa for F at least 2, 13.00 kPa for F at least 3, and 16.00 kPa for F=4. The areas under the receiver operating characteristic curve of FS and FT for F at least 2 were 0.88 versus 0.78 in the viral CLD group and 0.81 versus 0.70 in the nonviral CLD group and 0.87 versus 0.80 in all patients. The areas under the receiver operating characteristic curve for A at least 2 in all patients was 0.83. The optimal cutoff for A at least 2 was 0.50.
FT/AT is a reliable method for predicting significant liver fibrosis and necroinflammation in both viral and nonviral CLD patients with a value measurement comparable with that of the FS.

Download full-text


Available from: Bernard Portmann,
  • Source
    • "In acti-test, we used an additional index ALT as a sixth biomarker. Total bilirubin, GGT and ALT alpha 2 macroglobulin, Haptoglobin, and Apolipoprotein A1 were entered into the specifically designed algorithm in order to score hepatic dysfunction [Anastasiou et al., 2010; Boursier et al., 2009]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accurate monitoring of liver fibrosis changes in patients with hepatitis C virus (HCV) infection would be helpful in defining the need to intervene, implement the appropriate response in treatment and to minimize the use of liver biopsy. We aimed to evaluate the diagnostic utility of the different serum markers and indices in detecting liver fibrosis in study patients. Initial liver biopsy, routine liver function tests, estimation of hyaluronic acid, MMP-1, and PIIINP levels was performed for 30 Egyptian patients with HCV and 15 controls. Marker algorithms based on common laboratory such APRI score, Fibrotest and Actitest. PIIINP and MMP-1 serum markers were combined and entered into a stepwise logistic regression analysis with formulation of a score equation for fibrosis staging. Combined PIIINP and MMP-1 yielded different cut off scores to estimate two clinically relevant fibrosis stages: "significant fibrosis" versus "extensive fibrosis. Apri score also showed AUC of 1.0 with 100 % sensitivity and specificity to exclude the presence of cirrhosis and was significantly correlated to Metavair fibrosis stage in early fibrosis. On the other hand, PIIINP, Fibrotest and acti test were significantly correlated to Metavair fibrosis stage in both early and late fibrosis. In conclusion, integrating PIIINP/MMP-1 score was able to provide reliable information about the degree of liver fibrosis in chronic hepatitis C patients using different cut-offs values. A combination of liver markers as well as its related indices is an emerging tool to differentiate early from advanced liver fibrosis in HCV patients.
    The Egyptian journal of immunology / Egyptian Association of Immunologists 01/2011; 18(2):1-12.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The noninvasive quantitation of liver stiffness (LS) by ultrasound based transient elastography using FibroScan ® has revolutionized the diagnosis of liver diseases, namely liver cirrhosis. Alternative techniques such as acoustic radiation impulse frequency imaging or magnetic resonance elastography are currently under investigation. LS is an excellent sur-rogate marker of advanced fibrosis (F3) and cirrhosis (F4) outscoring all previous noninvasive approaches to detect cirrhosis. LS values below 6 kPa are considered as normal and exclude ongoing liver disease. LS of 8 and 12.5 kPa represent generally accepted cut-off values for F3 and F4 fibrosis. LS highly correlates with portal pressure, and esophageal varices are likely at values .20 kPa. Many other factors may also increase LS such as hepatic infiltration with tumor cells, mast cells (mastocytosis), inflammatory cells (all forms of hepatitis) or amyloidosis. In addition, LS is directly correlated with the venous pressure (eg, during liver congestion) and is increased during mechanic cholestasis. Thus, LS should always be interpreted in the context of clinical, imaging and laboratory findings. Finally, LS has helped to better understand the molecular mechanisms underlying liver fibrosis. The novel pressure-stiffness-fibrosis sequence hypothesis is introduced.
    Hepatic Medicine: Evidence and Research 05/2010; 2:49-67. DOI:10.2147/HMER.S7394
  • [Show abstract] [Hide abstract]
    ABSTRACT: ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity validated in patients with chronic hepatitis C (HCV). The aim was to assess the accuracy of AT in comparison with alanine aminotransferase (ALT) the standard of care. Methods used an integrated database of individual data and the new recommended Obuchowski measures. An updated "classical" meta-analysis of AT validation studies was also performed. The main end points were the area under the ROC curves (AUROCs) for the diagnosis of each histological activity grade defined using METAVIR scoring system. To avoid repeated tests and the spectrum effect of activity grades prevalence, the comparison of AT and ALT accuracies used the Obuchowski method. For the individual analysis, a total of 1250 patients were included and for the meta-analysis six studies (2017 patients) were included. The overall accuracy of AT for the diagnosis of any activity grade (Obuchowski measure=0.850) was significantly higher than the accuracy of ALT (Obuchowski measure=0.837; P=0.009). The updated standard meta-analysis confirmed the accuracy of AT (p<0.0001) both in independent AUROC=0.79 (95% CI, 0.73-0.85) and in non independent studies AUROC=0.74 (95% CI, 0.67-0.81). The accuracy of AT for grading the necro-inflammatory activity of patients with HCV was significantly higher than ALT serum activity alone, the standard biomarker.
    Gastroentérologie Clinique et Biologique 08/2010; 34(6-7):388-96. DOI:10.1016/j.gcb.2010.05.001 · 1.14 Impact Factor
Show more